Acorda Therapeutics to Present at H.C. Wainwright Global Life Sciences Virtual Conference
March 08 2021 - 5:44PM
Business Wire
Acorda Therapeutics, Inc. (NASDAQ: ACOR) announced that Ron
Cohen, M.D., President and Chief Executive Officer, will present
during the March 9th & 10th H.C. Wainwright Global Life
Sciences Virtual Conference. For more information about the
conference, please visit the event website at
https://hcwevents.com/globalconference/.
About Acorda Therapeutics
Acorda Therapeutics develops therapies to restore function and
improve the lives of people with neurological disorders. INBRIJA®
(levodopa inhalation powder) is approved for intermittent treatment
of OFF episodes in adults with Parkinson’s disease treated with
carbidopa/levodopa. INBRIJA is not to be used by patients who take
or have taken a nonselective monoamine oxidase inhibitor such as
phenelzine or tranylcypromine within the last two weeks. INBRIJA
utilizes Acorda’s innovative ARCUS® pulmonary delivery system, a
technology platform designed to deliver medication through
inhalation. Acorda also markets the branded AMPYRA® (dalfampridine)
Extended Release Tablets, 10 mg.
Forward-Looking Statements
This press release includes forward-looking statements. All
statements, other than statements of historical facts, regarding
management's expectations, beliefs, goals, plans or prospects
should be considered forward-looking. These statements are subject
to risks and uncertainties that could cause actual results to
differ materially, including: we may not be able to successfully
market AMPYRA, INBRIJA or any other products under development; the
COVID-19 pandemic, including related quarantines and travel
restrictions, and the potential for the illness to affect our
employees or consultants or those that work for other companies we
rely upon, could have a material adverse effect on our business
operations or product sales; our ability to raise additional funds
to finance our operations, repay outstanding indebtedness or
satisfy other obligations, and our ability to control our costs or
reduce planned expenditures; risks associated with the trading of
our common stock and our reverse stock split; risks related to our
workforce, including our ability to realize the expected benefits
of our corporate restructuring; risks associated with complex,
regulated manufacturing processes for pharmaceuticals, which could
affect whether we have sufficient commercial supply of INBRIJA to
meet market demand; our reliance on third-party manufacturers for
the production of commercial supplies of AMPYRA and INBRIJA; third
party payers (including governmental agencies) may not reimburse
for the use of INBRIJA or our other products at acceptable rates or
at all and may impose restrictive prior authorization requirements
that limit or block prescriptions; competition for INBRIJA, AMPYRA
and other products we may develop and market in the future,
including increasing competition and accompanying loss of revenues
in the U.S. from generic versions of AMPYRA (dalfampridine)
following our loss of patent exclusivity; the ability to realize
the benefits anticipated from acquisitions, among other reasons
because acquired development programs are generally subject to all
the risks inherent in the drug development process and our
knowledge of the risks specifically relevant to acquired programs
generally improves over time; the risk of unfavorable results from
future studies of INBRIJA (levodopa inhalation powder) or from our
other research and development programs, or any other acquired or
in-licensed programs; the occurrence of adverse safety events with
our products; the outcome (by judgment or settlement) and costs of
legal, administrative or regulatory proceedings, investigations or
inspections, including, without limitation, collective,
representative or class action litigation; failure to protect our
intellectual property, to defend against the intellectual property
claims of others or to obtain third party intellectual property
licenses needed for the commercialization of our products; and
failure to comply with regulatory requirements could result in
adverse action by regulatory agencies.
These and other risks are described in greater detail in our
filings with the Securities and Exchange Commission. We may not
actually achieve the goals or plans described in our
forward-looking statements, and investors should not place undue
reliance on these statements. Forward-looking statements made in
this press release are made only as of the date hereof, and we
disclaim any intent or obligation to update any forward-looking
statements as a result of developments occurring after the date of
this press release.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210308005911/en/
Tierney Saccavino (917) 783-0251 tsaccavino@acorda.com
Acorda Therapeutics (NASDAQ:ACOR)
Historical Stock Chart
From Aug 2024 to Sep 2024
Acorda Therapeutics (NASDAQ:ACOR)
Historical Stock Chart
From Sep 2023 to Sep 2024